Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Onglyza

Novartis building

FDA panel rejects Novartis’ heart failure hope serelaxin

Decision follows EMA knock back earlier this year

- PMLiVE

EMA clears GSK’s diabetes therapy Eperzan

Once-weekly GLP-1 therapy will line-up against Victoza and Byetta

- PMLiVE

AstraZeneca launches delivery service for Nexium

Expands its US direct-to-patient programme

Novartis building

More bad news for Novartis on heart failure candidate

FDA reviewers recommend against approving serelaxin

Otsuka’s Samsca heads clutch of Japanese approvals

Astellas' Xtandi, AstraZeneca's Forxiga and Takeda's Zacras also given the green light

- PMLiVE

Pfizer’s meningitis vaccine ‘a breakthrough’

FDA to speed up review process for bivalent rLP2086

- PMLiVE

Celgene gets FDA OK for first oral psoriatic arthritis drug

Otezla wins US approval to treat the auto-immune disease

- PMLiVE

Boehringer/Lilly’s empagliflozin among CHMP recommendations

If approved it will be marketed as Jardiance

AstraZeneca to develop mHealth cardiovascular services

Willwork with Vodafone in a new global partnership

National Institute for Health and Care Excellence NICE logo

Boehringer cancer drug on course for NHS use in UK

NICE backs Giotrif in draft guidance

- PMLiVE

Novo Nordisk will build $100m facility in Denmark

Bagsvaerd site will support growing diabetes pipeline

- PMLiVE

MedImmune appoints Dr Anand Subramony

He joins from Novartis to take up drug delivery and device development role

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links